Finland
EpiHeart, founded in 2019 and based in Finland, is a promising player in the Health Care and Manufacturing sectors. Their focus is clear: enabling surgical administration of cutting-edge cellular and gene therapies aimed particularly at cardiac care.
Their innovation seeks to address significant challenges in the field of cardiac cellular therapy, specifically targeting ischemic cardiac scars and heart failure during CABG (Coronary Artery Bypass Grafting) or LVAD (Left Ventricular Assist Device) surgery. By doing so, EpiHeart is directly tackling the global burden of heart disease with potentially transformative solutions.
Despite not having reported any further investment rounds or specific investor involvement yet, EpiHeart's dedication to pioneering in cardiac treatment through novel medical devices positions it as an enticing prospect for potential investors looking to enter or expand within the healthcare innovation space.
